# Cabot Corp: financial statements, quarterly

CBT · NYSE · CIK 16040 · [Materials](/sectors/materials.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/cbt.md) · [Financials](/companies/cbt/financials.md) · [Filings](/companies/cbt/filings.md) · [Insiders](/companies/cbt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cbt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [965 d](/filings/0001193125-25-292412.md) | [958](/filings/0000950170-25-015513.md) | [1,019](/filings/0000950170-25-065336.md) | [1,016](/filings/0000950170-25-102921.md) | [1,001 d](/filings/0001193125-25-292412.md) | [955](/filings/0001193125-26-037240.md) | [936](/filings/0001193125-26-209067.md) | [923](/filings/0001193125-26-332489.md) | [899 d](/filings/0001193125-25-292412.md) | [849](/filings/0001193125-26-037240.md) | [904](/filings/0001193125-26-209067.md) | [982](/filings/0001193125-26-332489.md) |
| Cost of revenue | $m | [740 d](/filings/0001193125-25-292412.md) | [740](/filings/0000950170-25-015513.md) | [773](/filings/0000950170-25-065336.md) | [760](/filings/0000950170-25-102921.md) | [761 d](/filings/0001193125-25-292412.md) | [720](/filings/0001193125-26-037240.md) | [695](/filings/0001193125-26-209067.md) | [679](/filings/0001193125-26-332489.md) | [679 d](/filings/0001193125-25-292412.md) | [638](/filings/0001193125-26-037240.md) | [694](/filings/0001193125-26-209067.md) | [798](/filings/0001193125-26-332489.md) |
| Gross profit | $m | [225 d](/filings/0001193125-25-292412.md) | [218](/filings/0000950170-25-015513.md) | [246](/filings/0000950170-25-065336.md) | [256](/filings/0000950170-25-102921.md) | [240 d](/filings/0001193125-25-292412.md) | [235](/filings/0001193125-26-037240.md) | [241](/filings/0001193125-26-209067.md) | [244](/filings/0001193125-26-332489.md) | [220 d](/filings/0001193125-25-292412.md) | [211](/filings/0001193125-26-037240.md) | [210](/filings/0001193125-26-209067.md) | [184](/filings/0001193125-26-332489.md) |
| Research and development | $m | [14.0 d](/filings/0001193125-25-292412.md) | [15.0](/filings/0000950170-25-015513.md) | [15.0](/filings/0000950170-25-065336.md) | [16.0](/filings/0000950170-25-102921.md) | [17.0 d](/filings/0001193125-25-292412.md) | [14.0](/filings/0001193125-26-037240.md) | [15.0](/filings/0001193125-26-209067.md) | [15.0](/filings/0001193125-26-332489.md) | [15.0 d](/filings/0001193125-25-292412.md) | [13.0](/filings/0001193125-26-037240.md) | [14.0](/filings/0001193125-26-209067.md) | [13.0](/filings/0001193125-26-332489.md) |
| Selling, general and administrative | $m | [69.0 d](/filings/0001193125-25-292412.md) | [67.0](/filings/0000950170-25-015513.md) | [75.0](/filings/0000950170-25-065336.md) | [68.0](/filings/0000950170-25-102921.md) | [73.0 d](/filings/0001193125-25-292412.md) | [66.0](/filings/0001193125-26-037240.md) | [64.0](/filings/0001193125-26-209067.md) | [62.0](/filings/0001193125-26-332489.md) | [68.0 d](/filings/0001193125-25-292412.md) | [69.0](/filings/0001193125-26-037240.md) | [67.0](/filings/0001193125-26-209067.md) | [73.0](/filings/0001193125-26-332489.md) |
| Operating income | $m | [142 d](/filings/0001193125-25-292412.md) | [136](/filings/0000950170-25-015513.md) | [156](/filings/0000950170-25-065336.md) | [172](/filings/0000950170-25-102921.md) | [150 d](/filings/0001193125-25-292412.md) | [155](/filings/0001193125-26-037240.md) | [162](/filings/0001193125-26-209067.md) | [167](/filings/0001193125-26-332489.md) | [137 d](/filings/0001193125-25-292412.md) | [129](/filings/0001193125-26-037240.md) | [129](/filings/0001193125-26-209067.md) | [98.0](/filings/0001193125-26-332489.md) |
| Interest expense | $m | [21.0 d](/filings/0001193125-25-292412.md) | [22.0](/filings/0000950170-25-015513.md) | [21.0](/filings/0000950170-25-065336.md) | [19.0](/filings/0000950170-25-102921.md) | [19.0 d](/filings/0001193125-25-292412.md) | [18.0](/filings/0001193125-26-037240.md) | [19.0](/filings/0001193125-26-209067.md) | [19.0](/filings/0001193125-26-332489.md) | [20.0 d](/filings/0001193125-25-292412.md) | [18.0](/filings/0001193125-26-037240.md) | [18.0](/filings/0001193125-26-209067.md) | [18.0](/filings/0001193125-26-332489.md) |
| Income tax | $m | [(118) d](/filings/0001193125-25-292412.md) | [34.0](/filings/0000950170-25-015513.md) | [47.0](/filings/0000950170-25-065336.md) | [40.0](/filings/0000950170-25-102921.md) | [(10.0) d](/filings/0001193125-25-292412.md) | [41.0](/filings/0001193125-26-037240.md) | [49.0](/filings/0001193125-26-209067.md) | [43.0](/filings/0001193125-26-332489.md) | [63.0 d](/filings/0001193125-25-292412.md) | [37.0](/filings/0001193125-26-037240.md) | [44.0](/filings/0001193125-26-209067.md) | [46.0](/filings/0001193125-26-332489.md) |
| Net income | $m | [234 d](/filings/0001193125-25-292412.md) | [50.0](/filings/0000950170-25-015513.md) | [84.0](/filings/0000950170-25-065336.md) | [109](/filings/0000950170-25-102921.md) | [137 d](/filings/0001193125-25-292412.md) | [93.0](/filings/0001193125-26-037240.md) | [94.0](/filings/0001193125-26-209067.md) | [101](/filings/0001193125-26-332489.md) | [43.0 d](/filings/0001193125-25-292412.md) | [73.0](/filings/0001193125-26-037240.md) | [68.0](/filings/0001193125-26-209067.md) | [6.0](/filings/0001193125-26-332489.md) |
| Diluted EPS | $ per share | not reported | [0.88](/filings/0000950170-25-015513.md) | [1.49](/filings/0000950170-25-065336.md) | [1.94](/filings/0000950170-25-102921.md) | not reported | [1.67](/filings/0001193125-26-037240.md) | [1.69](/filings/0001193125-26-209067.md) | [1.86](/filings/0001193125-26-332489.md) | not reported | [1.37](/filings/0001193125-26-037240.md) | [1.27](/filings/0001193125-26-209067.md) | [0.12](/filings/0001193125-26-332489.md) |
| Basic EPS | $ per share | not reported | [0.88](/filings/0000950170-25-015513.md) | [1.50](/filings/0000950170-25-065336.md) | [1.96](/filings/0000950170-25-102921.md) | not reported | [1.69](/filings/0001193125-26-037240.md) | [1.71](/filings/0001193125-26-209067.md) | [1.87](/filings/0001193125-26-332489.md) | not reported | [1.38](/filings/0001193125-26-037240.md) | [1.27](/filings/0001193125-26-209067.md) | [0.12](/filings/0001193125-26-332489.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [238](/filings/0000950170-24-129210.md) | [244](/filings/0000950170-24-012680.md) | [206](/filings/0000950170-24-057010.md) | [197](/filings/0000950170-24-091675.md) | [223](/filings/0001193125-25-292412.md) | [183](/filings/0000950170-25-015513.md) | [213](/filings/0000950170-25-065336.md) | [239](/filings/0001193125-26-332489.md) | [258](/filings/0001193125-26-332489.md) | [230](/filings/0001193125-26-037240.md) | [252](/filings/0001193125-26-209067.md) | [250](/filings/0001193125-26-332489.md) |
| Current assets | $m | [1,626](/filings/0000950170-24-129210.md) | [1,692](/filings/0000950170-24-012680.md) | [1,605](/filings/0000950170-24-057010.md) | [1,591](/filings/0000950170-24-091675.md) | [1,605](/filings/0001193125-25-292412.md) | [1,496](/filings/0000950170-25-015513.md) | [1,603](/filings/0000950170-25-065336.md) | [1,573](/filings/0000950170-25-102921.md) | [1,539](/filings/0001193125-26-332489.md) | [1,457](/filings/0001193125-26-037240.md) | [1,547](/filings/0001193125-26-209067.md) | [1,665](/filings/0001193125-26-332489.md) |
| Total assets | $m | [3,604](/filings/0001193125-25-292412.md) | [3,695](/filings/0000950170-24-012680.md) | [3,596](/filings/0000950170-24-057010.md) | [3,580](/filings/0000950170-24-091675.md) | [3,736](/filings/0001193125-25-292412.md) | [3,642](/filings/0000950170-25-015513.md) | [3,784](/filings/0000950170-25-065336.md) | [3,837](/filings/0000950170-25-102921.md) | [3,815](/filings/0001193125-26-332489.md) | [3,757](/filings/0001193125-26-037240.md) | [3,897](/filings/0001193125-26-209067.md) | [3,975](/filings/0001193125-26-332489.md) |
| Current liabilities | $m | [822](/filings/0000950170-24-129210.md) | [830](/filings/0000950170-24-012680.md) | [718](/filings/0000950170-24-057010.md) | [717](/filings/0000950170-24-091675.md) | [772](/filings/0001193125-25-292412.md) | [747](/filings/0000950170-25-015513.md) | [818](/filings/0000950170-25-065336.md) | [740](/filings/0000950170-25-102921.md) | [957](/filings/0001193125-26-332489.md) | [874](/filings/0001193125-26-037240.md) | [1,068](/filings/0001193125-26-209067.md) | [1,135](/filings/0001193125-26-332489.md) |
| Long-term debt | $m | [1,094](/filings/0000950170-24-129210.md) | [1,098](/filings/0000950170-24-012680.md) | [1,088](/filings/0000950170-24-057010.md) | [1,083](/filings/0000950170-24-091675.md) | [1,087](/filings/0001193125-25-292412.md) | [1,089](/filings/0000950170-25-015513.md) | [1,090](/filings/0000950170-25-065336.md) | [1,105](/filings/0000950170-25-102921.md) | [856](/filings/0001193125-26-332489.md) | [854](/filings/0001193125-26-037240.md) | [863](/filings/0001193125-26-209067.md) | [828](/filings/0001193125-26-332489.md) |
| Current portion of debt | $m | [8.0](/filings/0000950170-24-129210.md) | [8.0](/filings/0000950170-24-012680.md) | [8.0](/filings/0000950170-24-057010.md) | [8.0](/filings/0000950170-24-091675.md) | [8.0](/filings/0001193125-25-292412.md) | [9.0](/filings/0000950170-25-015513.md) | [9.0](/filings/0000950170-25-065336.md) | [10.0](/filings/0000950170-25-102921.md) | [260](/filings/0001193125-26-332489.md) | [260](/filings/0001193125-26-037240.md) | [261](/filings/0001193125-26-209067.md) | [261](/filings/0001193125-26-332489.md) |
| Short-term borrowings | $m | [174](/filings/0000950170-24-129210.md) | [206](/filings/0000950170-24-012680.md) | [88.0](/filings/0000950170-24-057010.md) | [49.0](/filings/0000950170-24-091675.md) | [45.0](/filings/0001193125-25-292412.md) | [100](/filings/0000950170-25-015513.md) | [190](/filings/0000950170-25-065336.md) | [100](/filings/0000950170-25-102921.md) | [14.0](/filings/0001193125-26-332489.md) | [12.0](/filings/0001193125-26-037240.md) | [175](/filings/0001193125-26-209067.md) | [184](/filings/0001193125-26-332489.md) |
| Shareholders' equity | $m | [1,264](/filings/0000950170-24-129210.md) | [1,329](/filings/0000950170-24-012680.md) | [1,367](/filings/0000950170-24-057010.md) | [1,346](/filings/0000950170-24-091675.md) | [1,425](/filings/0001193125-25-292412.md) | [1,366](/filings/0000950170-25-015513.md) | [1,427](/filings/0000950170-25-065336.md) | [1,541](/filings/0000950170-25-102921.md) | [1,550](/filings/0001193125-26-332489.md) | [1,575](/filings/0001193125-26-037240.md) | [1,568](/filings/0001193125-26-209067.md) | [1,605](/filings/0001193125-26-332489.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [138 d](/filings/0001193125-25-292412.md) | [105](/filings/0000950170-25-015513.md) | [176 d](/filings/0000950170-25-065336.md) | [207 d](/filings/0000950170-25-102921.md) | [204 d](/filings/0001193125-25-292412.md) | [124](/filings/0001193125-26-037240.md) | [73.0 d](/filings/0001193125-26-209067.md) | [249 d](/filings/0001193125-26-332489.md) | [219 d](/filings/0001193125-25-292412.md) | [126](/filings/0001193125-26-037240.md) | [77.0 d](/filings/0001193125-26-209067.md) | [75.0 d](/filings/0001193125-26-332489.md) |
| Capital expenditure | $m | [78.0 d](/filings/0001193125-25-292412.md) | [54.0](/filings/0000950170-25-015513.md) | [43.0 d](/filings/0000950170-25-065336.md) | [52.0 d](/filings/0000950170-25-102921.md) | [92.0 d](/filings/0001193125-25-292412.md) | [77.0](/filings/0001193125-26-037240.md) | [72.0 d](/filings/0001193125-26-209067.md) | [61.0 d](/filings/0001193125-26-332489.md) | [64.0 d](/filings/0001193125-25-292412.md) | [69.0](/filings/0001193125-26-037240.md) | [45.0 d](/filings/0001193125-26-209067.md) | [38.0 d](/filings/0001193125-26-332489.md) |
| Dividends paid | $m | [23.0 d](/filings/0001193125-25-292412.md) | [22.0](/filings/0000950170-25-015513.md) | [23.0 d](/filings/0000950170-25-065336.md) | [24.0 d](/filings/0000950170-25-102921.md) | [24.0 d](/filings/0001193125-25-292412.md) | [24.0](/filings/0001193125-26-037240.md) | [23.0 d](/filings/0001193125-26-209067.md) | [24.0 d](/filings/0001193125-26-332489.md) | [25.0 d](/filings/0001193125-25-292412.md) | [24.0](/filings/0001193125-26-037240.md) | [24.0 d](/filings/0001193125-26-209067.md) | [24.0 d](/filings/0001193125-26-332489.md) |
| Share repurchases | $m | [50.0 d](/filings/0001193125-25-292412.md) | [33.0](/filings/0000950170-25-015513.md) | [24.0 d](/filings/0000950170-25-065336.md) | [49.0 d](/filings/0000950170-25-102921.md) | [66.0 d](/filings/0001193125-25-292412.md) | [42.0](/filings/0001193125-26-037240.md) | [47.0 d](/filings/0001193125-26-209067.md) | [40.0 d](/filings/0001193125-26-332489.md) | [39.0 d](/filings/0001193125-25-292412.md) | [52.0](/filings/0001193125-26-037240.md) | [49.0 d](/filings/0001193125-26-209067.md) | [0.0 d](/filings/0001193125-26-332489.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [56.7](/filings/0000950170-24-012680.md) | [56.8](/filings/0000950170-24-057010.md) | [56.5](/filings/0000950170-24-091675.md) | [55.8](/filings/0000950170-25-015513.md) | [55.8](/filings/0000950170-25-065336.md) | [55.7](/filings/0000950170-25-102921.md) | [55.0](/filings/0001193125-26-037240.md) | [54.4](/filings/0001193125-26-209067.md) | [53.8](/filings/0001193125-26-332489.md) | [52.9](/filings/0001193125-26-037240.md) | [52.2](/filings/0001193125-26-209067.md) | [52.0](/filings/0001193125-26-332489.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 51,631,007 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332489.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.